Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade

BACKGROUND: Immunogenicity of SARS-CoV-2 vaccines is modestly impaired in cancer patients due to a generally weakened immune system. Immune checkpoint inhibitors (ICI) are expected to enhance immune response. This has already been described to be the case in influenza vaccines, and first data about...

Descripción completa

Detalles Bibliográficos
Autores principales: Niewolik, Jacqueline, Mikuteit, Marie, Cossmann, Anne, Vahldiek, Kai, Gutzmer, Ralf, Müller, Frank, Schröder, Dominik, Heinemann, Stephanie, Behrens, Georg M.N., Dopfer-Jablonka, Alexandra, Steffens, Sandra, Grimmelmann, Imke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393793/
https://www.ncbi.nlm.nih.gov/pubmed/35609553
http://dx.doi.org/10.1159/000524894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393793/
https://www.ncbi.nlm.nih.gov/pubmed/35609553
http://dx.doi.org/10.1159/000524894

Ejemplares similares